Prescription medicine
Adalimumab-adaz Brand names: Hyrimoz
Adalimumab-adaz (Hyrimoz) is a prescription medicine with an FDA approval on record since 2018. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: adalimumab-adaz labels on DailyMed; the BLA 761071 record on Drugs@FDA; every adalimumab-adaz label on DailyMed.
Highlights of the record
no current FDA label; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
The label in openFDA carries no indications section.
Forms and strengths
Kit.
On the market
- Earliest approval on file
- October 30, 2018 Hyrimoz, Sandoz Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 52,465 through July 30, 2026
Is there a generic for adalimumab-adaz (Hyrimoz)?
No generic adalimumab-adaz is approved (Drugs@FDA, October 8, 2026).
- 2018 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the adalimumab-adaz label say about other medicines?
The adalimumab-adaz label names no other medicine on this site. The labels of 1 other medicine name adalimumab-adaz. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Other labels that name adalimumab-adaz
Source: FDA drug label, labeler not named, effective (SPL set ), via openFDA; the full label on DailyMed
What do FAERS reports show for adalimumab-adaz?
The FDA Adverse Event Reporting System holds 52,465 reports that list adalimumab-adaz among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 8,010 are coded as a death and 18,137 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (10,494, against a median of 3,158 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other TNF blockers
- the pharmacologic class, with prices and generics
- Adalimumab-adaz side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other